Minneapolis, MN, United States of America

Philip S Portoghese

This inventor holds 23 USPTO granted patents and 2 published patent applications and 1 EPO patent, primarily in Opioid Receptor Research. Top assignees: Regents of the University of Minnesota, Arizona State University, Minneapolis Medical Research Foundation. Active years: 1982-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Philip S Portoghese. Retrieved from https://idiyas.com/inventor/philip-s-portoghese

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 2)

% Patents Active = 95.7

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 1.7

ph-index = 11

Forward Citations = 771(Granted Patents)

Location History:

Falcon Heights, MN (US) (1987 - 1989)
Saint Paul, MN (US) (1982 - 2013)
Minneapolis, MN (US) (2018 - 2022)

Company Filing History:

21 out of 2,373

Regents of the University of Minnesota

patents

1 out of 2,166

Arizona State University

patents

1 out of 3

Minneapolis Medical Research Foundation

patents

4. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1982-2022

Loading Chart...

Areas of Expertise:

Analgesic Agents

Kappa Opioid Receptor Antagonists

Delta Opioid Receptor Antagonists

Therapeutic Compounds

Pain Treatment

Immunoregulatory Treatment

Non-Addictive Narcotics

Opiate Analogs

Selective Alkylating Agents

Cocaine Abuse Treatment

Opioid Receptor Activity

Gut-Selective Opiates

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11529340 - Combination for treating pain (2022-12-20),

2. 10464941 - Therapeutic compounds (2019-11-05),

3. 10034871 - Salts and compositions useful for treating disease (2018-07-31),

4. 9981043 - Analgesic conjugates (2018-05-29),

5. 8609682 - Analgesic agents (2013-12-17),

6. 7232829 - Therapeutic compounds and methods (2007-06-19),

7. 6534514 - Kappa opioid receptor antagonists (2003-03-18),

8. 6500824 - Kappa (OP2) opioid receptor antagonists (2002-12-31),

9. 6271239 - Delta opioid receptor-selective benzylidene-substituted morphinans (2001-08-07),

10. 5804595 - Kappa opioid receptor agonists (1998-09-08),

11. 5631263 - Use of delta opioid receptor antagonists to treat immunoregulatory (1997-05-20),

12. 5578725 - Delta opioid receptor antagonists (1996-11-26),

13. 5464841 - Use of delta opioid receptor antagonists to treat immunoregulatory (1995-11-07),

14. 5457208 - Kappa opioid receptor antagonists (1995-10-10),

15. 5411965 - Use of delta opioid receptor antagonists to treat cocaine abuse (1995-05-02),

Title: Exploring the Inventive Legacy of Philip S Portoghese

Introduction:

Philip S Portoghese, a prolific inventor based in Minneapolis, MN, has made significant contributions to the field of pain treatment through his innovative patented compounds and methods. With 23 patents to his name, Portoghese's work has had a lasting impact on pharmaceutical research and development.

Latest Patents:

Among his recent patents is a groundbreaking "Combination for treating pain," which introduces novel compounds and compositions for effective pain management. Additionally, his patent on "Therapeutic compounds" unveils a formula for pharmaceutical compositions and therapeutic methods aimed at alleviating pain.

Career Highlights:

Portoghese has lent his expertise to esteemed institutions such as the University of Minnesota and the Arizona Board of Regents, a Body Corporate. His multidimensional career showcases a dedication to advancing the field of pharmacology and pain management through cutting-edge innovation and research.

Collaborations:

Throughout his career, Philip S Portoghese has collaborated with notable peers in the industry, including Sandra L Olmsted and Burt M Sharp. This collaborative approach has led to the development of groundbreaking solutions and enhanced the impact of his inventive work in the scientific community.

Conclusion:

In conclusion, Philip S Portoghese stands as a pioneering figure in the realm of pain treatment innovation, with a remarkable portfolio of patents that continue to shape the landscape of pharmaceutical research. His contributions to the field highlight a commitment to excellence and a relentless pursuit of novel solutions for improving patient outcomes.

Profile summary based on public USPTO records.